N4 Pharma (GB:N4P) has released an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
N4 Pharma has filed a new patent for its innovative oral anti-inflammatory product targeting Irritable Bowel Disease (IBD) using its proprietary Nuvec® delivery system. The product aims to replace current treatments with significant side effects by utilizing nanoparticles to deliver RNA that inhibits inflammation and boosts natural defenses in the gut. This development highlights N4 Pharma’s commitment to advancing RNA therapeutics and attracting potential investors and collaborators.
For further insights into GB:N4P stock, check out TipRanks’ Stock Analysis page.
